ALNY financials
Alnylam Pharmaceuticals, Inc. · end-of-day data as of Oct 16, 2026
Alnylam Pharmaceuticals, Inc.
$231.83-14.7%
Buy · 30 analystsPT $374.49 +61.5%
ALNY reported revenue of $1.29B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 66.9% from a year earlier. It posted diluted EPS of $1.20, free cash flow of $40.64M and a net margin of 12.7%.
Valuation
- P/E39.2x
- P/E vs own-92.9%
- P/E vs sector+39.1%
- FCF yield+1.7%
- Market cap$31.02B
Quarterly results
Q2 FY2026: Revenue +66.9% year over year, free cash flow 3.1% of revenue, operating margin 17.9%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $1.29B | 1.20 | $40.64M | 76.9% | 17.9% | 12.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.17B | 1.51 | $48.67M | 81.9% | 23.0% | 17.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.1B | 1.37 | $140M | 75.6% | 12.0% | 17.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.25B | 1.84 | $313M | 84.2% | 29.5% | 20.1% |
| Q2 FY2025 | Jun 30, 2025 | $774M | -0.51 | $139M | 81.5% | -2.1% | -8.6% |
| Q1 FY2025 | Mar 31, 2025 | $594M | -0.44 | -$127M | 88.0% | 3.0% | -9.7% |
| Q4 FY2024 | Dec 31, 2024 | $593M | -0.65 | -$104M | 82.7% | -17.7% | -14.1% |
| Q3 FY2024 | Sep 30, 2024 | $501M | -0.87 | $39.52M | 82.9% | -15.4% | -22.3% |
| Q2 FY2024 | Jun 30, 2024 | $660M | -0.13 | $116M | 89.6% | 7.4% | -2.6% |
| Q1 FY2024 | Mar 31, 2024 | $494M | -0.52 | -$94.49M | 86.7% | -8.8% | -13.3% |
| Q4 FY2023 | Dec 31, 2023 | $440M | -1.10 | -$45.1M | 80.5% | -26.5% | -31.4% |
| Q3 FY2023 | Sep 30, 2023 | $751M | 1.15 | $342M | 88.8% | 28.5% | 19.7% |